3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
5
Recruiting
4
Active not recruiting
3
Not yet recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
158
Gynecologic
66
Breast
42
Genitourinary
18
Head & Neck
17
Gastrointestinal
17
Lymphoid
15
Other solid neoplasm
14
CNS
12
Sarcoma
11
Tumor-Agnostic
8
Dermatologic
5
Other hematologic neoplasm
3
Classical hematology
3
Plasma cell
1
Myeloid
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Everolimus
10
lanreotide
4
Capecitabine
4
pasireotide
3
lutetium Lu 177 dotatate
3
lenvatinib
3
fosbretabulin
3
Temozolomide
3
Sorafenib
3
Paclitaxel
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
Erlotinib Hydrochloride
3
Doxorubicin
3
trifluridine tipiracil drug combination
2
surufatinib
2
pembrolizumab
2
pegfilgrastim
2
gallium Ga 68 dotatate
2
durvalumab
2
dactolisib
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Sunitinib
2
Rosiglitazone
2
Radiotherapy
2
Panobinostat
2
Mitotane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carboplatin
×
Endocrine
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts